Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Patient-Reported Outcomes Measures in Psoriasis

Patient-Reported Outcomes Measures in Psoriasis Psoriasis, a chronic systemic inflammatory disease, has a substantial impact on patients’ quality of life (QoL): physical limitations, psychologic impact, social embarrassment, and occupational burden, as well as treatment-related complications. This paper discusses some of the uses and limitations of commonly used patient-reported outcomes (PRO) in psoriasis. We reviewed 260 papers including original research and systemic review papers looking into the PRO used in psoriasis clinical trials. Although there is still no single best PRO measure in psoriasis nor in any other disease, it was interesting to examine the common instruments that are used in psoriasis clinical trials, especially those involving newly innovated biologics as Interleukin 17 inhibitors, and assessing the psychometric properties. The International Dermatology Outcome Measures works with patients, health care providers, payers, and regulators to develop validated patient-centered clinical outcome measures for clinical research as well as clinical practice. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Psoriasis and Psoriatic Arthritis SAGE

Loading next page...
 
/lp/sage/patient-reported-outcomes-measures-in-psoriasis-EPitDMaFYb

References (41)

Publisher
SAGE
Copyright
© 2017 National Psoriasis Foundation.
ISSN
2475-5303
eISSN
2475-5311
DOI
10.1177/247553031700200303
Publisher site
See Article on Publisher Site

Abstract

Psoriasis, a chronic systemic inflammatory disease, has a substantial impact on patients’ quality of life (QoL): physical limitations, psychologic impact, social embarrassment, and occupational burden, as well as treatment-related complications. This paper discusses some of the uses and limitations of commonly used patient-reported outcomes (PRO) in psoriasis. We reviewed 260 papers including original research and systemic review papers looking into the PRO used in psoriasis clinical trials. Although there is still no single best PRO measure in psoriasis nor in any other disease, it was interesting to examine the common instruments that are used in psoriasis clinical trials, especially those involving newly innovated biologics as Interleukin 17 inhibitors, and assessing the psychometric properties. The International Dermatology Outcome Measures works with patients, health care providers, payers, and regulators to develop validated patient-centered clinical outcome measures for clinical research as well as clinical practice.

Journal

Journal of Psoriasis and Psoriatic ArthritisSAGE

Published: Jun 1, 2017

There are no references for this article.